#IGMS - Long Term TargetThis targets are also including fundamental analysis but also technical.
Our strategy is based on complicated research so I want to simplfy and just have to give targets.
Risk/Reward ratio is 3.91 which is very good
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.68 USD
−246.42 M USD
2.13 M USD
20.69 M
About IGM Biosciences, Inc.
Sector
CEO
Mary Beth Harler
Headquarters
Mountain View
Website
Founded
2010
FIGI
BBG00PNR1BT2
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm’s product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.
Pay attention to IGMS... :-)Pay attention to IGMS...
Gets out of shuffling with high trading volume
Entrance - $14.50
First target - $28
Second target - $46
NASDAQ:IGMS
IGMS a cash burning biotechnology stock SHORTIGMS is down about 70% YTD with no end is sight as the cash burn is greater than
the analyst's estimates.On the 2H chart, the midline of the Bollinger Bands has had
a persistent negative slope. Overall, IGMS is very shortable if shares can be found at
a low cost. I will watch for a correction
( IGMS ) DOWN WE GO! According to my graph analysis, IGMS is over bought and doesn’t seem to have anymore room to continue it’s upward trend. As presented within the chart on a 15 minute time frame, it was rejected 2 times before descending down a bit. Sell now!
Ichimoku entry IGMSDecisive cloudbreak with perfect alignment on the cloud twist and lagging span crossover.
stoploss: 62.58
trailing stop: 2.31, conditional on price reaching 76.44
IGMS likely bullish .NASDAQ:IGMS is likely to continue up towards the 74 , It might return to bounce off the white line before continuing towards the 74 .
But If the green line is closed above significantly in an upcoming day there would be a considerable chance that it would continue up towards the 97-100 green rectan
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where IGMS is featured.
Frequently Asked Questions
The current price of IGMS is 13.16 USD — it has decreased by −1.44% in the past 24 hours. Watch IGM Biosciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange IGM Biosciences, Inc. stocks are traded under the ticker IGMS.
IGMS stock has fallen by −16.94% compared to the previous week, the month change is a 4.74% rise, over the last year IGM Biosciences, Inc. has showed a 153.96% increase.
We've gathered analysts' opinions on IGM Biosciences, Inc. future price: according to them, IGMS price has a max estimate of 48.00 USD and a min estimate of 9.00 USD. Watch IGMS chart and read a more detailed IGM Biosciences, Inc. stock forecast: see what analysts think of IGM Biosciences, Inc. and suggest that you do with its stocks.
IGMS reached its all-time high on Dec 9, 2020 with the price of 133.00 USD, and its all-time low was 3.81 USD and was reached on Nov 1, 2023. View more price dynamics on IGMS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
IGMS stock is 12.72% volatile and has beta coefficient of 3.15. Track IGM Biosciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is IGM Biosciences, Inc. there?
Today IGM Biosciences, Inc. has the market capitalization of 852.41 M, it has increased by 11.11% over the last week.
Yes, you can track IGM Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
IGM Biosciences, Inc. is going to release the next earnings report on Mar 27, 2025. Keep track of upcoming events with our Earnings Calendar.
IGMS earnings for the last quarter are −1.01 USD per share, whereas the estimation was −0.80 USD resulting in a −26.25% surprise. The estimated earnings for the next quarter are −0.72 USD per share. See more details about IGM Biosciences, Inc. earnings.
IGM Biosciences, Inc. revenue for the last quarter amounts to 516.00 K USD, despite the estimated figure of 230.56 K USD. In the next quarter, revenue is expected to reach 177.78 K USD.
IGMS net income for the last quarter is −47.90 M USD, while the quarter before that showed −49.82 M USD of net income which accounts for 3.84% change. Track more IGM Biosciences, Inc. financial stats to get the full picture.
No, IGMS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 8, 2024, the company has 224.00 employees. See our rating of the largest employees — is IGM Biosciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. IGM Biosciences, Inc. EBITDA is −228.00 M USD, and current EBITDA margin is −11.98 K%. See more stats in IGM Biosciences, Inc. financial statements.
Like other stocks, IGMS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IGM Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So IGM Biosciences, Inc. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating IGM Biosciences, Inc. stock shows the sell signal. See more of IGM Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.